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Abstract
Introduction: In a murine model, interleukin (IL)-17 plays a critical role in the pathogenesis of arthritis. There are
controversies, however, regarding whether IL-17 is a proinflammatory mediator in rheumatoid arthritis (RA). We
previously established an ex vivo cellular model using synovial tissue (ST)-derived inflammatory cells, which
reproduced pannus-like tissue growth and osteoclastic activity in vitro. Using this model, we investigated the
effects of IL-17 on pannus growth and osteoclastogenesis in RA.
Methods: Inflammatory cells that infiltrated synovial tissue from patients with RA were collected without enzyme
digestion and designated as ST-derived inflammatory cells. ST-derived inflammatory cells were cultured in the
presence or absence of IL-17 or indomethacin, and the morphologic changes were observed for 4 weeks.
Cytokines produced in the culture supernatants were measured by using enzyme-linked immunosorbent assay kits.
Osteoclastic activity was assessed by the development of resorption pits in calcium phosphate-coated slides.
Results: Exogenous addition of IL-17 dramatically enhanced the spontaneous production of IL-6 and prostaglandin
E2 (PGE2) by the ST-derived inflammatory cells, while it had no effect on the production of tumor necrosis factor
(TNF)-a and macrophage colony-stimulating factor (M-CSF). Furthermore, IL-17 did not affect the spontaneous
development of pannus-like tissue growth and osteoclastic activity by the ST-derived inflammatory cells. On the
other hand, IL-17 enhanced pannus-like tissue growth, the production of TNF-a and M-CSF and the development
of osteoclastic activity in the presence of indomethacin, an inhibitor of endogenous prostanoid production, while
exogenous addition of PGE1 suppressed their activities.
Conclusions: The present study suggests that IL-17 induces negative feedback regulation through the induction of
PGE2, while it stimulates proinflammatory pathways such as inflammatory cytokine production, pannus growth and
osteoclastogenesis in RA.
Introduction
Rheumatoid arthritis (RA) is chronic autoimmune
inflammatory disease that ultimately leads to the pro-
gressive destruction of cartilage and bone in numerous
joints. Proinflammatory cytokines such as tumor necro-
sis factor (TNF)-a [1], interleukin (IL)-1 [2] and IL-6 [3]
were produced from synovial tissue (ST), which main-
tains its inflammatory condition. Inflammation of syno-
vial membrane results in the development of aggressive
granulation tissue, called pannus. Pannus tissue is
composed mainly of inflammatory cells such as macro-
phages and fibroblast-like synoviocytes (FLSs) [4].
At present, TNF-a and IL-6 are among the most
important targets of therapy, and blocking TNF-a results
in a rapid and sustained improvement of clinical signs
and symptoms [5-7]. Anti-TNF therapy also prevents
radiological progression of joint destruction [8-10]. Anti-
IL-6 receptor monoclonal antibody (mAb) (tocilizumab)
has also proved to reduce disease activity, even in
patients who had an insufficient response to anti-TNF
therapy, and to inhibit the progression of structural joint
damage [11-13]. These clinical experiences suggest that
there are at least two pathways, TNF-a-dependent and
IL-6-dependent, leading to the progression of pannus
growth and joint destruction in RA.
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17, which is produced by a newly identified subset of
CD4
+ T cells, Th-17, in animal models of arthritis
[14,15]. In humans, IL-17 is a potent inducer of other
proinflammatory cytokines, such as TNF-a,I L - 1 b,I L - 6
and IL-8 from monocytes and/or macrophages or syno-
vial fibroblasts [16,17]. IL-17 has been detected in syno-
vial fluids of RA [18,19]. These findings suggest that
IL-17 is an important cytokine located upstream of the
two pathways, TNF-a-dependent and IL-6-dependent.
Preliminary clinical trial using humanized anti-IL-17 mAb
has shown an improvement of clinical signs and symptoms
of RA [20]. It is still unknown, however, whether inhibi-
tion of IL-17 prevents joint destruction in RA.
To further confirm the hypothesis, the present study
was undertaken to clarify a role of IL-17 in RA using
our recently established ex vivo human cellular model,
where rheumatoid ST-derived inflammatory cells spon-
taneously develop pannus-like tissue in vitro and osteo-
clastic bone resorption [21].
Materials and methods
Reagents
IL-17 was purchased from PeproTech (Rocky Hill, NJ,
USA). PGE1 was purchased from Sigma-Aldrich (St.
Louis, MO, USA). Indomethacin was obtained from
Wako (Osaka, Japan).
Synovial tissue specimens
ST specimens were obtained from patients who fulfilled
the American College of Rheumatology criteria for RA
who underwent knee joint replacement. In compliance
with institutional policies, informed consent was
obtained from all patients. The study was approved by
the ethics committee of each institution.
In vitro reconstruction of inflammatory tissue by ST-
derived inflammatory cells
ST-derived inflammatory cells were prepared as pre-
viously described [21]. In brief, ST specimens were cut
into small pieces and cultured in 100-mm dishes contain-
ing RPMI-1640 (Asahi Technoglass, Chiba, Japan) with
10% fetal calf serum (FCS) and 1,000 U/ml penicillin G
sodium-streptomycin sulfate (Gibco BRL, Grand Island,
NY, USA). After 1 to 3 days’ incubation, tissue was
removed and single cells were collected by vigorous
pipetting. Cell suspensions were washed once, and viable
cells were collected into Lymphocyte Separation Medium
(Nacalai Tesque, Kyoto, Japan). Single suspensions of ST-
derived inflammatory cells were seeded at a density of
5×1 0
5/well in 48-well culture plates and cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco
BRL) containing 10% FCS, 100 U/ml penicillin G sodium
and 100 μg/ml streptomycin sulfate. The culture was
observed for morphologic changes under an inverted
phase-contrast microscope twice a week for 4 weeks.
When cultured in DMEM and 10% FCS in the absence
or presence of IL-17 (0.1 to 100 ng/ml) or indomethacin
(100 nM to 1 μM), ST-derived inflammatory cells started
to aggregate, forming foci within a few days. Further cul-
turing resulted in three-dimensional (3-D) growth, which
ultimately produced macroscopic tissue 2 mm in size
within 4 weeks. Morphologic changes were semiquantita-
tively scored on a scale of 0 to 4, according to the degree
of tissue development, where 0 was no cellular foci or
aggregations, 1 was the formation of cellular foci or
aggregation, 2 was further growth of cellular aggrega-
tions, 3 was further 3-D growth with a multilayered
structure, and 4 was the development of macroscopic tis-
sue. Cumulative tissue growth score was calculated by
the total sum of the tissue growth scores obtained twice
weekly for 4 weeks of culture. Half of the supernatants
were collected twice weekly and replaced with fresh med-
ium or the addition of a half dose of IL-17 or indometha-
cin. Supernatants were frozen at -80°C until assayed.
Cytokine assay
ST-derived inflammatory cells were seeded in 48-well
culture plates (5 × 10
5/well) and cultured in DMEM
and 10% FCS.
Half of the supernatants were collected three times per
week and replaced with fresh medium. Supernatants were
frozen at -80°C until assayed, and levels of IL-6, PGE2,
TNF-a and M-CSF (all from R&D Systems, Minneapolis,
MN, USA) released into the culture supernatants were
measured using enzyme-linked immunosorbent assay kits
according to the manufacturers’ recommendations.
Bone resorption assay
ST-derived inflammatory cells were seeded (1 × 10
5
cells/well) onto calcium phosphate-coated slides (Osteo-
logic; BD Biosciences, MA, USA) and incubated in
RPMI-1640 with 1% FCS, 50 μg/ml ascorbic acid
(Sigma) and 10 mM b-glycerophosphate (Sigma) for 7
to 14 days in a CO2 incubator (5% CO2,1 0 0 %h u m i d i t y
at 37°C). Half of the supernatants were replaced with
fresh medium once weekly. The calcium phosphate-
coated slides were washed with distilled water and
bleach solution (6% NaOCl and 5.2% NaCl) and then
air-dried. The number of resorption pits were counted
under a microscope.
Results
IL-17 enhances IL-6 and PGE2 production by ST-derived
inflammatory cells
Using a recently established ex vivo cellular model of
RA, we examined the effect of IL-17 on the production
of IL-6 and PGE2 by the ST-derived inflammatory cells.
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spontaneously produced IL-6 and PGE2 in the superna-
tant as shown in Figure 1. Addition of IL-17 into the
culture resulted in the enhancement of both IL-6 and
PGE2 production in a dose-dependent manner.
Effect of IL-17 on the development of pannus-like
inflammatory tissue in vitro by the ST-derived
inflammatory cells
We have reported that ST-derived inflammatory cells
showed spontaneous development of pannus-like tissue
in vitro [21]. The ST-derived inflammatory cells at the
beginning of the culture contained 1.6% to 4.2% FLSs
(mean, 2.6%), 35.8% to 65.7% macrophages (mean,
53.7%) and 32.4% to 62.6% small lymphocytes (mean,
44.7%) when assessed by morphological observation.
During the culture of ST-derived inflammatory cells,
marked proliferation and migration of the FLSs into the
pannus-like tissue were observed. At the end of culture,
pannus-like tissue contained more than 80% FLSs and
less than 10% of macrophages and T cells as assessed by
immunohistochemistry. As IL-17 enhanced IL-6 and
PGE2 production by the ST-derived inflammatory cells,
we investigated the effect of IL-17 on the development
of pannus-like tissue in vitro. The cumulative tissue
growth score during 4 weeks of culturing of ST-derived
inflammatory cells was not affected by the addition of
I L - 1 7u pt o1 0 0n g / m l ,w h i l ei tw a ss u p p r e s s e db yt h e
exogenous addition of 100 nM PGE1 (Figure 2) as well
as 100 nM PGE2 (data not shown).
These results suggested that the effect of IL-17 on the
development of pannus-like tissue was modified by IL-
17-enhanced endogenous PGE2 production. To confirm
this possibility, we investigated the effect of indometha-
cin, an inhibitor of endogenous prostanoids, on the pan-
nus-like tissue growth in vitro. Addition of indomethacin
resulted in a significant enhancement of the in vitro
tissue growth by the ST-derived inflammatory cells
(Figure 3). In the presence of indomethacin, the in vitro
tissue growth was enhanced by the addition of IL-17 in a
dose-dependent manner.
IL-17 enhances M-CSF and TNF-a production by ST-
derived inflammatory cells in the presence of
indomethacin
Rheumatoid ST contains a number of proinflammatory
cytokines that influence osteoclast formation and bone
resorption. Proinflammatory cytokines such as TNF-a and
IL-6 stimulate differentiation and activation of osteoclasts,
resulting in increased bone resorption. M-CSF is constitu-
tively produced by synovial fibroblasts from RA patients
and contributes to the differentiation of synovial macro-
phages into osteoclasts. We investigated the effect of IL-17
on M-CSF and TNF-a production from ST-derived
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Figure 1 Effect of interleukin (IL)-17 on the production of (A) IL-6 (A) and (B) prostaglandin E2 (PGE2) by the synovial tissue (ST)-
derived inflammatory cells. Cells were incubated in the absence or presence of increasing concentrations of IL-17 (0 to 100 ng/ml) for 3
weeks. IL-6 (n = 7) and PGE2 (n = 3) in the culture supernatants were measured by enzyme-linked immunosorbent assay as described in
Materials and methods.
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inflammatory cells spontaneously produced M-CSF and
TNF-a in the supernatant as described previously [21].
Contrary to our expectation, spontaneous production of
both M-CSF and TNF-a was not affected by the addition
of IL-17 up to100 ng/ml (Figures 4A and 4B).
As PGE2 is known to inhibit the production of M-CSF
and TNF-a from macrophages and synovial fibroblasts
[22,23], respectively, we examined the effect of IL-17 on
the production of M-CSF and TNF-a in the presence of
indomethacin to block the effect of endogenous PGE2.
In the presence of indomethacin, IL-17 significantly
enhanced the production of M-CSF and TNF-a in a
dose-dependent manner (Figures 4A and 4B), while IL-
17-induced IL-6 production was not affected by the
addition of indomethacin (Figure 4C).
IL-17 stimulates osteoclastic bone resorption
We previously showed that ST-derived inflammatory cells
in a 1% FCS-containing medium showed spontaneous
Figure 2 Effect of interleukin (IL)-17 and prostaglandin E1 (PGE1) on pannus-like tissue growth in vitro.S y n o v i a lt i s s u e( S T ) - d e r i v e d
inflammatory cells were incubated in the absence or presence of increasing concentrations of IL-17 (0 to 100 ng/ml) (n = 17) or PGE1 (100 nM)
(n = 9). Morphologic changes were observed under an inverted phase contrast microscope twice weekly for 4 weeks and were scored
semiquantitatively on a scale of 0 to 4 according to the degree of tissue development as described in Materials and methods. Box and whisker
plots indicate 25th/75th percentile and minimum/maximum, respectively. Bar indicates the median value. *P < 0.001 (by Mann-Whitney U test).
Ito et al. Arthritis Research & Therapy 2011, 13:R14
http://arthritis-research.com/content/13/1/R14
Page 4 of 11development of multinucleated giant cells within 2 weeks.
They were tartrate-resistant acid phosphatase-positive
multinucleated cells and developed numerous resorption
pits when incubated on a calcium phosphate-coated slide
[21]. Exogenous addition of IL-17 tended to increase the
number of resorption pits, but the difference did not reach
statistical significance (Figure 5). Indomethacin signifi-
cantly enhanced the development of resorption pits by the
ST-derived inflammatory cells. In the presence of indo-
methacin, IL-17 significantly increased the number of
resorption pits in a dose-dependent manner (Figure 5).
Discussion
Inflammation in general is fundamentally a protective
response against cellular and tissue injury caused by
diverse pathological stimuli, and it is closely intertwined
Figure 3 Effect of interleukin (IL)-17 on pannus-like tissue growth in the presence of indomethacin.S y n o v i a lt i s s u e( S T ) - d e r i v e d
inflammatory cells (n = 7) were incubated with an incremental dose of IL-17 in the absence or presence of indomethacin (100 to 1000 nM).
Morphologic changes were observed under an inverted phase contrast microscope twice weekly for 4 weeks and were scored semiquantitatively
on a scale of 0 to 4 according to the degree of tissue development as described in Materials and methods. Box and whisker plots indicate 25th/
75th percentile and minimum/maximum, respectively. Bar indicates the median value. *P < 0.05 (by Wilcoxon signed-rank test).
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inflammation and tissue repair are not successfully com-
pleted and inflammation perpetuates chronically. RA is
characterized by chronic inflammation of the synovial
membrane, which results in the development of aggres-
sive granulation tissue, so-called pannus, and the subse-
quent destruction of cartilage and bone. Pannus tissue is
composed mainly of invasive phenotype of FLSs, lym-
phocytes and activated macrophages, and in the case of
bone erosion, monocyte-derived osteoclasts [4]. Cyto-
kine networks and cell-cell interaction, as well as other
inflammatory mediators, such as prostanoids, contribute
to the development of pannus tissue and osteoclastic
activity. This complex system of rheumatoid synovitis
includes both positive and negative feedback regulation
of inflammatory responses. Therefore, a human cell
model that represents this complex system will be useful
to study the role of IL-17 in the pathogenesis of RA. We
previously established an ex vivo cellular model using
the ST-derived inflammatory cells, which reproduced
pannus-like tissue growth and osteoclastic activity
in vitro. Using this model, the present study demon-
strated that IL-17 enhanced production of proinflamma-
tory cytokines, pannus-like tissue growth and
osteoclastic activity by the ST-derived inflammatory
cells, while IL-17 simultaneously induced negative feed-
back regulation through the enhanced production of
PGE2, a potent deactivator of macrophages and other
inflammatory modulator [24]. Inhibition of endogenous
PGE2 production resulted in the enhancement of pan-
nus growth and osteoclastic activity. Therefore, the net
effects of IL-17 may depend upon the balance between
the positive and negative regulatory responses.
IL-17 is an important proinflammatory cytokine
involved in the pathogenesis of RA. Previous studies have
shown that IL-17 is present in rheumatoid synovial fluid
and can upregulate several mediators of inflammation,
such as TNF-a, IL-1, IL-6, IL-8 and matrix metalloprotei-
nases (MMPs), in FLS. Among other cytokines, both
TNF-a and IL-6 have been shown to play a pivotal role in
the progression of RA. The importance of TNF-a and IL-
6 in the pathogenesis of RA has been established by the
clinical experiences with anti-TNF and anti-IL-6 therapy
[5-7,11,13]. Blocking TNF-a by either neutralizing mAbs
(infliximab and adalimumab) or soluble TNF receptor-
immunoglobulin G (IgG)-Fc fusion protein (etanercept)
resulted in a rapid and sustained improvement of clinical
signs and symptoms in both early and advanced RA. Anti-
TNF therapy also prevented radiological progression of
joint destruction [8-10]. Anti-IL-6 receptor mAb (tocilizu-
mab) has also been proved to reduce disease activity, even
in patients who had insufficient response to anti-TNF
therapy [12], and to inhibit the progression of structural
joint damage [11,13]. These clinical experiences suggest
that there are at least two pathways, TNF-a-dependent
and IL-6-dependent, leading to the progression of pannus
growth and joint destruction in RA. IL-17 has been shown
to stimulate TNF-a and IL-6 expression [16,17], suggest-
ing that IL-17 is an important cytokine located upstream
of the two pathways.
PGE2 has been established as a regulator of cytokine
production by activated macrophages. PGE2 inhibits the
ABC
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Figure 4 Effect of interleukin (IL)-17 on the production of macrophage colony-stimulating factor (M-CSF), tumor necrosis factor a
(TNF-a) and IL-6. Synovial tissue (ST)-derived inflammatory cells were incubated with incremental doses of IL-17 in the absence or presence of
indomethacin (100 to 1,000 nM) for 1 week. Enzyme-linked immunosorbent assay kits were used to measure the concentration of (A) TNF-a, (B)
M-CSF and IL-6 (C) in the culture supernatants derived from seven donors. There were no significant differences in the production of IL-6
between the presence and absence of indomethacin. Box and whisker plots indicate 25th/75th percentile and minimum/maximum, respectively.
Bar indicates the median value. *P < 0.05 (by Wilcoxon signed-rank test).
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Page 6 of 11production of TNF-a, IL-6, IL-8 and IL-12 and downre-
gulates the expression of IL-12 receptor on macrophages
[23,25,26]. PGE2 downregulates TNF-a and upregulates
IL-10 through the EP2 and EP4 receptors. This effect of
PGE2 can reverse cytokine disequilibrium from proin-
flammatory toward anti-inflammatory [24,27]. PGE2 has
been reported to suppress IL-17-induced TNF-a mRNA
expression and protein synthesis in human macrophages
and synovial fibroblasts from RA patients via EP4 recep-
tor- and EGR-1-mediated inhibition of c-Jun expression
[28]. PGE2 induces egr-1 mRNA expression and protein
synthesis by activating transcription factor 2 (ATF-2)
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Figure 5 Effect of interleukin (IL)-17 on the osteoclastogenesis. Osteoclastic activity was assessed by the development of resorption pits in
calcium phosphate-coated slides as described in Materials and methods. Synovial tissue (ST)-derived inflammatory cells (n = 6) were cultured
with incremental doses of IL-17 in the absence or presence of indomethacin on calcium phosphate-coated slides for 2 weeks and examined for
the development of resorption pits. The ratio to the number of resorption pits in medium alone was plotted. Bar indicates the median value. *P
< 0.05 vs. medium alone (by Wilcoxon signed-rank test).
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upregulated promoter activity was largely dependent on
ATF-2/c-Jun transactivation. PGE2 suppression of IL-17-
induced ATF-2/c-Jun transactivation, and DNA binding
was dependent on egr-1-mediated inhibition of the
induced c-Jun expression. While upregulating TNF-a
expression, IL-17 also induces cyclooxygenase 2
(COX2)/PGE2 expression, which in turn downregulates
TNF-a expression. This negative feedback regulation of
TNF-a expression by PGE2 may be critical in the modu-
lation of the immune and inflammatory responses in
RA. The present study has demonstrated that IL-17-
induced TNF-a production, pannus-like tissue growth
and osteoclastic activity by the ST-derived inflammatory
cells were effectively downregulated by the negative
feedback loop through PGE2 production, while IL-17-
induced IL-6 production was not.
PGE2 has been shown to inhibit IL-6 production by
activated human macrophages [26], while other studies
have shown that PGE2 enhanced IL-6 production by IL-
1b-stimulated human synovial fibroblasts and osteo-
blasts, as well as chondrocytes [22,29,30]. The present
s t u d yh a ss h o w nt h a tt h en e te f f e c to fI L - 1 7o nI L - 6
production by the ST-derived inflammatory cells was
n o ta f f e c t e db yt h ee n d o g e n o u sP G E 2. This result sug-
gests that the effect of IL-17 is mainly mediated by the
IL-6 pathway, while the TNF-a pathway is downregu-
lated by endogenous PGE2.
In RA, increased FLS proliferation and/or decreased
FLS apoptosis contributes to synovial hyperplasia and
pannus growth [31]. IL-17 has been shown to induce
proliferation of FLS through the induction of Cyr61, a
product of a growth factor-inducible immediate early
gene, and the subsequent expression of Bcl-2 that pre-
vents RA FLS apoptosis [32]. COX2-derived PGE2 inhi-
bits IL-1/TNF-a-stimulated MMP-1 release from FLSs
via inhibition of extracellular signal-regulated kinase
(ERK) [33]. On the contrary, COX inhibitors attenuated
PGE2 inhibition of ERK and enhanced the release of
MMP-1 by FLSs [33]. IL-1b and TNF-a stimulate the
translocation of p65 and p50 from the cytosol to the
nucleus and activate NF-B in human RA synovial
fibroblasts [27]. PGE2 inhibits p65 translocation via inhi-
bition of ERK activation and also enhances the expres-
sion of IBa in an ERK-independent manner, suggesting
that PGE2 inhibits NF-B activation by both ERK-
dependent and ERK-independent mechanisms. These
data indicate that PGE2 may act to attenuate cytokine-
induced inflammatory responses in RA synovial fibro-
blasts by regulating the localization of specific NF-B
family dimers [27].
In summary, there is accumulating evidence that sug-
gests a molecular cross-talk mechanism involving COX2
and PGE2 expression in the resolution of inflammation.
Proinflammatory cytokines, including IL-17 and TNF-a,
play a critical role in the progression of synovitis and
joint destruction, mainly through activation of NF-B,
while they directly induce COX2 and PGE2 expression.
PGE2 upregulates COX2 expression via EP2 and EP4
receptors and cyclic adenosine monophosphate-depen-
dent signaling pathway, which in turn modulates the
production of the proinflammatory molecules. The link
between proinflammaory molecules and PGE2 could
have considerable importance in the regulation of
inflammatory cell activation of RA. The paracrine and
autocrine feedback mechanisms via COX2, PGE2,E P 2
and EP4 could help to avoid the potential pathological
damage caused by the excessive production of inflam-
matory mediators in response to various biological sti-
muli in RA.
In the present study, we used PGE1 instead of PGE2 as
the exogenous source of cell cultures (Figure 2). Pre-
vious studies indicated that PGE1 and PGE2 are equiva-
lent in terms of biological effects on human synovial
fibroblast proliferation [34] and their binding affinity to
PGE2-specific receptors EP1,E P 2,E P 3 and EP4 [35]. Our
preliminary data also shows that both PGE1 and PGE2
equivalently inhibited both FLS proliferation and in vitro
pannus-like tissue growth by the ST-derived inflamma-
tory cells in a dose-dependent manner (data not shown).
The reason why we have used PGE1 instead of PGE2
was the fact that we were intending to develop a novel
therapeutic strategy utilizing anti-inflammatory effects of
PGE1. There have been several attempts to use PGE1 to
treat autoimmune and inflammatory diseases such as
adjuvant arthritis [36] and lupus nephritis [37]. We also
published the inhibitory effect of lipid microsphere-
incorporated PGE1 in a collagen-induced arthritis model
[38].
Osteoclastic bone resorption is another important
feature of pannus tissue in RA. Receptor activator of
NF-B ligand (RANKL) and M-CSF are essential for
osteoclastogenesis [39,40]. The expression of RANKL on
activated T cells, osteoblasts and synovial fibroblasts
contribute to osteoclastic bone resorption in RA
patients. M-CSF is constitutively produced by synovial
fibroblasts from RA patients and contributes to the dif-
ferentiation of synovial macrophages into osteoclasts in
collaboration with RANKL [41]. In humans, IL-17
induced the expression of both RANK on osteoclast pre-
cursors [42] and RANKL on synovial fibroblast [43]. A
recent study showed that TNF-induced RANKL expres-
sion was IL-6-dependent [44]. On the other hand, both
TNF-a and IL-6 also stimulate osteoclastogenesis in a
RANKL-independent manner [45,46]. In the present
study, we have demonstrated that IL-17 also stimulated
M-CSF production by the ST-derived inflammatory
cells. The result is consistent with a recent report that
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row-derived mesenchymal stem cells [47].
Another important question is whether IL-17-
enhanced osteoclastogenesis under the suppression of
endogenous prostanoids is TNF-dependent and/or
IL-6-dependent. IL-17 is known to stimulate RANKL
expression on fibroblast-like synoviocytes through the
induction of IL-6 [44]. On the other hand, IL-17 is
reported to induce osteoclast formation through RANK
expression on osteoclast precursors [42]. Whether this
effect is TNF-dependent and/or IL-6-dependent remains
unknown. These questions require further studies
including experiments neutralizing TNF-a and IL-6.
Proinflammatory cytokines such as TNF-a and IL-6
have been known to stimulate osteoclastogenesis
through enhancing RANKL expression. IL-17, an indu-
cer of TNF-a and IL-6 expression, is also a potent sti-
mulator of osteoclastogenesis in RA. In animal models,
it has been reported that TNF-a and IL-1b stimulate
osteoclastogenesis through PGE2 [48]. Recently, one of
these research groups demonstrated that, in contrast to
mouse macrophage cultures, PGE2 inhibited RANKL-
induced human osteoclast formation in CD14
+ cell
cultures [49]. In our cellular model of RA, we demon-
strated that IL-17 enhanced osteoclastogenesis by the
ST-derived inflammatory cells only when endogenous
prostanoid production was inhibited by indomethacin.
The result can be explained by the fact that IL-17-
induced TNF-a and M-CSF production was downregu-
lated by the simultaneous induction of endogenous
PGE2. The present study also leads to a clinically impor-
tant suggestion that suppression of PGE2 by the contin-
uous use of nonsteroidal anti-inflammatory drugs
(NSAIDs) such as indomethacin may augment TNF-a
pathway-dependent pannus growth and osteoclastic
bone resorption, resulting in the joint destruction in RA
[24].
Conclusions
Using a human cellular model of pannus, we have
demonstrated that IL-17 induced both proinflammatory
cascades, including TNF-a and IL-6, as well as negative
feedback regulation by PGE2 production. The positive
effect of IL-17 on pannus-like tissue growth and osteo-
clastic activity by the ST-derived inflammatory cells was
effectively downregulated by the simultaneously induced
endogenous PGE2. The negative feedback mechanisms
via PGE2 could help to avoid the potential pathological
damage caused by the excessive production of mediators
in response to various biological stimuli such as IL-17
in RA. Whether continuous inhibition of PGE2 by the
administration of NSAIDs and COX2 inhibitors could
augment pannus growth and joint destruction remains
to be clarified.
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